Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.
Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.
We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...
Pharmaceutical stocks can bring an element of safety to your portfolio. All of this equals a rather steady stream of revenue ...
From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.
We recently compiled a list of the 10 Best Halal Dividend Stocks To Invest In. In this article, we are going to take a look ...
The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...
AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...
AbbVie also spoke about the disappointing data from Phase II studies of emraclidine in schizophrenia – a drug acquired as part of its $9bn acquisition of Cerevel. The company unveiled data in November ...
Cerevel Therapeutics (Cerevel), a subsidiary of AbbVie Inc, is a clinical-stage biopharmaceutical company that develops therapies to treat neuroscience diseases. The company’s product pipeline ...
“As AbbVie's chief scientific officer ... 10.1 billion takeover of ImmunoGen and a planned $8 billion acquisition of Cerevel, which hasn’t yet been completed.